An immunosuppressant, FK506, protects against neuronal dysfunction and death but has no effect on electrographic and behavioral activities induced by systemic kainate.
Kainate is a potent agonist of an excitatory amino acid receptor subtype in the central nervous system, and causes neuronal death in several regions of the brain. Neurons are preferentially killed in the hippocampus, especially in the CA1 region, by systemic administration of kainate. It is speculated that functional alterations occur in the neurons preceding death. We examined the effect of FK506 on kainate-induced neuronal death and functional alterations in the rat hippocampal CA1 region. FK506 had no effect on electrographic and behavioral seizure activities induced by kainate; however, it prevented neuronal death measured seven days after administration. Although neither death nor morphological alterations of neurons were observed in the CA1 region 24 h after administration, the neurons exhibited decreased excitatory postsynaptic potentials and enhanced long-term potentiation. This functional alteration was not detected in the rats administered FK506 prior to kainate. Taken together, these observations indicate that functional alteration precedes neuronal death in rats systemically administered kainate and that FK506 prevents both. It is suggested that FK506 exerts its neuroprotective effect not by attenuating electrographic and behavioral seizure activities, but by protecting neurons from kainate-induced functional disorders.
Moriwaki
A
A
First Department of Physiology, Okayama University Medical School, Japan.
Lu
Y F
YF
Tomizawa
K
K
Matsui
H
H
D000344:Afferent Pathways / Q000187:drug effects / Q000502:physiology; D000679:Amygdala / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D016923:Cell Death / Q000187:drug effects; D002540:Cerebral Cortex / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology; D004569:Electroencephalography / Q000187:drug effects*; D006624:Hippocampus / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007608:Kainic Acid / Q000494:pharmacology*; D008297:Male; D009412:Nerve Fibers / Q000187:drug effects / Q000502:physiology; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D012044:Regression Analysis; D012640:Seizures / Q000139:chemically induced / Q000503:physiopathology*; D016559:Tacrolimus / Q000494:pharmacology*; D013997:Time Factors
D007166:Immunosuppressive Agents; D007608:Kainic Acid; D016559:Tacrolimus